Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Long-term potentiation (LTP) and Long-term depression (LTD) of hippocampal synaptic transmission represent the principal experimental models underlying learning and memory. Alterations of synaptic plasticity are observed in several neurodegenerative disorders including Alzheimer’s disease (AD). Indeed, synaptic dysfunction is an early event in AD, making it an attractive therapeutic target for pharmaceutical intervention. To date, intensive investigations have characterized hippocampal synaptic transmission, LTP and LTD in in vitro and in murine models of AD. In this review we describe the synaptic alterations across the main AD models generated so far. We then examine the clinical perspective of LTP/LTD studies and discuss the limitations of non-clinical models and how to improve their predictive validity in the drug discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 3×
“…of LTP and LTD is largely used in many different experimental conditions and animal models as an indicator of cognitive function; on the other hand, dysregulation of synaptic plasticity underlies a large number of neurodegenerative disorders such as Alzheimer’s disease (AD) (Selkoe, 2002).”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Malenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 5×
“Concerning the functional aspects, 6-month-old 3xTg mice display impairment of LTP (Oddo et al., 2003), which correlates with intracellular Aβ well before plaque and tangle pathology.”
BackgroundMethodInfluentialDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“…that treatment of hippocampal slices with Aβo 200–500 nM induces alteration in LTP and LTD, generally manifested as loss of LTP and enhancement of LTD (Lambert et al., 1998; Wang et al., 2002; Shankar et al., 2008; Li et al., 2009; Jo et al., 2011; Cavallucci et al., 2013; Mango et al., 2016).”
BackgroundPalop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Generally, the predictive value of non-clinical models in the drug discovery process has been largely debated independently of the therapeutic area (McGonigle and Ruggeri, 2014; Mullane and Williams, 2019).”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 1×
“We have previously hypothesized that alterations in normal synaptic function are not only a key feature but also a leading cause of disease (Nisticò and Collingridge, 2012).”
BackgroundA mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
Long-term depression in the CNS
Collingridge, G. L., Peineau, S., Howland, J. G., & Wang, Y. T. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2867 · Cited by 926
Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740 · cited 1×
“Specifically, it has been demonstrated that NR2B-containing NMDA receptors and mGlu5 receptors mediate the synaptotoxic effects of Aβo (Rammes et al., 2017).”
BackgroundAnimal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610 · cited 1×
“Correct design of nonclinical studies can be a long, complex, and expensive process that may slow down the course of drug development (Mohs and Greig, 2017); nonetheless, the probability of successful approval and hence time saving and return on investment is certainly increased.”
BackgroundCaspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease
D'Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., Diamantini, A., De Zio, D., Carrara, P., Battistini, L., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2709 · Cited by 572
Wang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., et al. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03058-x · Cited by 527 · cited 1×
“…that treatment of hippocampal slices with Aβo 200–500 nM induces alteration in LTP and LTD, generally manifested as loss of LTP and enhancement of LTD (Lambert et al., 1998; Wang et al., 2002; Shankar et al., 2008; Li et al., 2009; Jo et al., 2011; Cavallucci et al., 2013; Mango et al., 2016).”
BackgroundGong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
BDNF mechanisms in late LTP formation: A synthesis and breakdown
Panja, D., & Bramham, C. R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.024 · Cited by 336
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Long-term potentiation and long-term depression: a clinical perspective
Bliss, T. V. P., & Cooke, S. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300002 · Cited by 333
Kimura, R., & Ohno, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.006 · Cited by 333
Hippocampal LTP and contextual learning require surface diffusion of AMPA receptors
Penn, A. C., Zhang, C. L., Georges, F., Royer, L., Breillat, C., Hosy, E., Petersen, J. D., Humeau, Y., & Choquet, D. (2017) · Nature · doi:10.1038/nature23658 · Cited by 324
Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation
Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E. J., Tunbridge, E. M., Denk, F., Dawson, H. N., Vitek, M. P., Wade-Martins, R., Paulsen, O., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2610-10.2011 · Cited by 315 · cited 1×
“Early impairments in synaptic transmission were highlighted in different mouse models of AD and are caused, among other factors, by Aβ which leads to impairment of LTP via tau protein (Shipton et al., 2011).”
BackgroundAβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305 · cited 1×
“…that treatment of hippocampal slices with Aβo 200–500 nM induces alteration in LTP and LTD, generally manifested as loss of LTP and enhancement of LTD (Lambert et al., 1998; Wang et al., 2002; Shankar et al., 2008; Li et al., 2009; Jo et al., 2011; Cavallucci et al., 2013; Mango et al., 2016).”
BackgroundTemporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
Ohno, M., Cole, S. L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., Disterhoft, J. F., & Vassar, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.008 · Cited by 290
Prion protein and Aβ‐related synaptic toxicity impairment
Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., & Aguzzi, A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000082 · Cited by 242
Zhang, J., Malik, A., Choi, H. B., Ko, R. W. Y., Dissing-Olesen, L., & MacVicar, B. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.043 · Cited by 234 · cited 1×
“Other chemical forms of LTD are obtained either by exogenous application of NMDA or muscarinic receptor agonists (reviewed by Collingridge et al., 2010), as well as through activation of microglia (Zhang et al., 2014).”
BackgroundAMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice
Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., Shirao, T., Aoki, C., & Huerta, P. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507313103 · Cited by 225
The synaptic Aβ hypothesis of Alzheimer disease
Tanzi, R. E. (2005) · Nature Neuroscience · doi:10.1038/nn0805-977 · Cited by 206
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172 · cited 1×
“Among the key players facilitating the transition from E-LTP to L-LTP, brain-derived neurotrophic factor (BDNF) (Panja and Bramham, 2014) and transforming growth factor β1 (TGF-β1) (Caraci et al., 2015; Caraci et al., 2018) are noteworthy.”
BackgroundA Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory
Morley, J. E., Farr, S. A., Banks, W. A., Johnson, S. N., Yamada, K. A., & Xu, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1230 · Cited by 141 · cited 1×
“…during physiologic neuronal activity and causes enhancement of synaptic plasticity and memory formation when administered at picomolar concentrations that likely resemble the physiological level in the brain (Puzzo et al., 2008; Morley et al., 2010; Puzzo et al., 2011; Lawrence et al., 2014).”
BackgroundPhosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117 · cited 1×
“Recently, other triple transgenic mice have been generated harboring APP, PS2, and tau mutations (Rhein et al., 2009; Grueninger et al., 2010) but electrophysiological investigations have not been performed so far.”
BackgroundCholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice
Perez, S. E., He, B., Muhammad, N., Oh, K.-J., Fahnestock, M., Ikonomovic, M. D., & Mufson, E. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.002 · Cited by 80 · cited 1×
“…during physiologic neuronal activity and causes enhancement of synaptic plasticity and memory formation when administered at picomolar concentrations that likely resemble the physiological level in the brain (Puzzo et al., 2008; Morley et al., 2010; Puzzo et al., 2011; Lawrence et al., 2014).”
Background
Cited by
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K., & Ju, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 395
Viayna, E., Coquelle, N., Cieslikiewicz-Bouet, M., Cisternas, P., Oliva, C. A., Sánchez-López, E., Ettcheto, M., Bartolini, M., De Simone, A., Ricchini, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01775 · Cited by 106
Bhattacharyya, R., Black, S. E., Lotlikar, M. S., Fenn, R. H., Jorfi, M., Kovacs, D. M., & Tanzi, R. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109134 · Cited by 84
Neural ageing and synaptic plasticity: prioritizing brain health in healthy longevity
Navakkode, S., & Kennedy, B. K. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1428244 · Cited by 75
Bi, W., Bao, K., Zhou, X., Deng, Y., Li, X., Zhang, J., Lan, X., Zhao, J., Lu, D., Xu, Y., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02904-9 · Cited by 36
“Synaptic plasticity is the basis of learning and memory [40] and hippocampal synaptic function damage occurs before memory loss, Aβ deposition, and neuronal cell death [41].”
Background
Metadata
- Authors
- Mango, D., Saidi, A., Cisale, G. Y., Feligioni, M., Corbo, M., & Nisticò, R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-16
- Volume
- 10
- Pages
- 778-778
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2957992914
- Cited by
- 107
- References
- 41
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.